This feature highlights changes in clinical trial organizations’ personnel.

Abalos Therapeutics

Dethardt Müller has been appointed to the role of chief technology officer at Abalos Therapeutics. Prior to this appointment, Müller was head of chemistry manufacturing and controls at ViraTherapeutics.

Aerami Therapeutics

Timm Crowder has been named Aerami Therapeutics’ chief operating officer. Most recently, Crowder served as chief operating officer at SPYRYX Biosciences.

Aerie Pharmaceuticals

Aerie Pharmaceuticals has hired Michelle Senchyna, who will move into the position of vice president of clinical development and medical affairs. Most recently, Senchyna was executive director of clinical development at Allergan.

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals has found its first chief financial officer in Jeffrey Trigilio. Prior to this role, Trigilio was vice president of finance at BlueRock Therapeutics.

ArisGlobal

ArisGlobal has hired Clint Wolfe as the firm’s new chief human resources officer. Previously, Wolfe was executive vice president of global human resources at Bioclinica. ArisGlobal has also named Andras Berta as the company’s new chief strategy officer, after serving as a former executive at Gedeon Richter and Vifor Pharma. Rick Simpson has also joined ArisGlobal, serving as chief financial officer. Prior to this role, Simpson was a former finance executive at SaaS.

Avidity Biosciences

Avidity Biosciences has named Joseph Baroldi as the firm’s new chief operating officer. Previously, Baroldi was vice president of business development at Ionis Pharmaceuticals.

Biomarin

Executive vice president and chief financial officer Dan Spiegelman has transitioned to the role of senior adviser, which he will maintain until a replacement is hired. In the interim, senior vice president of finance and chief accounting officer Brian Mueller will act as the Biomarin’s temporary chief financial officer.

Boston Pharmaceuticals

Craig Basson has joined Boston Pharmaceuticals as the company’s new chief medical officer. Prior to taking this position, Basson was vice president and global translational medicine head of cardiovascular and metabolism research at Novartis.

Catalent

Jim Walter has joined Catalent as the company’s vice president of operations for oral and specialty delivery. Before taking this role, Walter was senior vice president of operations and engineering at Tinuum Group.

Crescendo Biologics

Kenji Hashimoto, who has most recently led the clinical development of a checkpoint inhibitor in renal cell carcinoma at Roche, has joined Crescendo Biologics as the company’s new chief medical officer.

CytomX Therapeutics

CytomX Therapeutics announced the appointment of Alison Hannah as the firm’s new chief medical officer. Prior to this appointment, Hannah served as an oncology clinical trial consultant.

Domainex

Tom Mander has been appointed to the role of CEO at Domainex, taking over the role when the company’s CEO Trevor Perrior retires in April 2020. Currently, Mander is chief operating officer at Domainex.

Dyne Therapeutics

Dyne Therapeutics has tapped Oxana Beskrovnaya as the company’s new senior vice president and head of research. Previously, Beskrovnaya was head of musculoskeletal and renal research in Sanofi’s rare disease and neurological unit. Chris Mix has also been named Dyne’s senior vice president of clinical development. Most recently, Mix served as vice president of rare genetic disease clinical development at Agios Pharmaceuticals. Additionally, Dyne has hired John Najim as the firm’s new vice president of chemistry, manufacturing and controls. Prior to this position, Najimn was vice president of manufacturing and process development as well as associate director of manufacturing at Dyax Corporation.

Encoded Therapeutics

Salvador Rico has been named chief medical officer at Encoded Therapeutics, joining the company after serving as senior vice president of clinical development at Audentes Therapeutics. Martin Moorhead has been promoted to the role of chief technology officer. Previously, Moorhead was head of technology at Encoded.

Enteris BioPharma

Gary Shangold has joined Enteris BioPharma, assuming the role of chief medical officer. Currently, Shangold serves as CEO of InteguRx Therapeutics.

Enterprise Therapeutics

David Morris has been appointed to the role of chief medical officer at Enterprise Therapeutics, joining the firm from Novartis Venture Fund, where he serves as managing director. Morris will continue to serve as an operating partner at Novartis.

Epirium Bio

Ransi Somaratne has been appointed to the role of chief medical officer at Epirium Bio. Prior to this appointment, Somaratne was a core team leader at BioMarin Pharmaceutical.

Frequency Therapeutics

Frequency Therapeutics has appointed Wendy Arnold to the role of chief people officer. Previously, Arnold was senior vice president of human resources at Kaleido BioSciences. Lisa Geller has also joined Frequency as the firm’s new head of intellectual property. Most recently, Geller was head of intellectual property at Casebia Therapeutics.

Galecto

Galecto has named Bertil Lindmark as the company’s new chief medical officer. Previously, Lindmark was the chief medical officer at eTheRNA Immunotherapies.

Ichnos Sciences

Gabriela Gruia has joined Ichnos Sciences as its new chief development officer. Previously, Gruia was senior vice president and global head of drug regulatory affairs at Novarits.

Imara

Joelle Lufkin has been appointed to the role of senior vice president of development at Imara. Lufkin was most recently the vice president of clinical development at Flexion Therapeutics.

Lyndra Therapeutics

Richard Scranton has been named chief medical officer at Lyndra Therapeutics, joining the company from Pacira Pharmaceuticals where he served as chief medical officer.

Millendo Therapeutics

Christophe Arbet-Engels has been appointed to the role of chief medical officer at Millendo Therapeutics. Arbet-Engels joins Millendo after serving as chief medical officer and executive vice president late development and medical affairs at Poxel Pharmaceuticals.

Nymox

Russell I. Thomson has been named vice president of quality and regulatory affairs at Nymox. Previously, Thomson was a chartered scientist with the Science Council (UK) from 2004 to 2010.

Palleon Pharmaceuticals

Palleon Pharmaceuticals has announced the appointment of Li Peng to the role of chief scientific officer. Most recently, Peng was senior vice president of research and early product development at Palleon.

Pharvaris

Peng Lu, who most recently served as vice president and global program lead for rare diseases at Takeda, has joined Pharvaris as its chief medical officer.

Portola Pharmaceuticals

Rajiv Patni has assumed the role of executive vice president and chief medical officer at Portola Pharmaceuticals. Most recently, Patni was chief medical officer at Adamas Pharmaceuticals.

SELLAS Life Sciences Group

Dragan Cicic has been named senior vice president of clinical development at SELLAS Life Sciences Group. Prior to this appointment, Cicic was senior vice president and clinical lead at Klus Pharma.

TB Alliance

Daniel Everitt has been named vice president and chief medical officer at TB Alliance, a promotion from his previous role as TB’s senior medical officer.

Terrace Global

Stephen Lermer has been named Terrace Global’s new president and chief operating officer. Previously, Lermer was chief operating officer of Charlotte’s Web Holdings.

Trefoil Therapeutics

Trefoil Therapeutics has appointed Thomas Tremblay to the role of vice president of clinical development. Most recently, Tremblay was vice president of clinical affairs and head of clinical operations and clinical compliance at Hallux.

Truvian

Truvian has appointed Shane Bowen to the position of head of engineering. Before joining Truvian, Bowen was the global leader in DNA sequencing and array-based technologies at Illumina, serving as senior director of scientific research in the department of research and technology development.

Vividion Therapeutics

Robert Abraham has joined Vividion Therapeutics as the biotech company’s new chief scientific officer. Abraham was most recently a cancer research head at Pfizer.